Antibodies
16 October 2015
Kolltan Pharmaceuticals Announces Interim Efficacy Data from KTN3379 Phase 1b Clinical Trial13 October 2015
Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine13 October 2015
Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program13 October 2015
New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide13 October 2015
New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis12 October 2015
Global strategic partners bioeq and Formycon initiate pivotal phase III clinical trial with their Lucentis® biosimilar5 October 2015
Atara Bio’s PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet5 October 2015
Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF5 October 2015
Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab)1 October 2015
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis29 September 2015
Ablynx initiates a multinational phase III study with caplacizumab in patients with acquired TTP, a rare blood clotting disorderNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports